

# ForPatients

by Roche

Multiple Sclerosis (MS)

## A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

**Trial Status**  
Withdrawn

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT05208840 ML42302

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### ***Trial Summary:***

This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS). In addition, this study will investigate if the presence of leptomeningeal inflammation is associated with alterations of B cell repertoire and whether therapy with ocrelizumab will lead to change of B cell repertoire in LMCE-positive patients.

**Hoffmann-La Roche**  
Sponsor

**Phase 4**  
Phase

---

**NCT05208840 ML42302**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 65 Years

**Healthy Volunteers**  
No

---